Tufia C Haddad Selected Research

Anemia

1/2023

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tufia C Haddad Research Topics

Disease

27	Breast Neoplasms (Breast Cancer) 05/2024 - 12/2014
19	Neoplasms (Cancer) 01/2024 - 01/2006
5	Triple Negative Breast Neoplasms 04/2022 - 07/2016
4	Heart Failure 01/2023 - 12/2014
3	Neutropenia 11/2023 - 10/2022
2	Ductal Carcinoma 07/2023 - 03/2023
2	Lymphoma (Lymphomas) 01/2023 - 01/2020
2	Fatigue 10/2022 - 01/2019
2	Residual Neoplasm 01/2022 - 07/2016
2	Disease Progression 01/2020 - 04/2018
2	Cardiotoxicity 09/2017 - 12/2014
1	Inflammatory Breast Neoplasms 01/2024
1	Overweight 11/2023
1	Anemia 01/2023
1	Mouth Neoplasms (Oral Cancer) 10/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 04/2022
1	Unilateral Breast Neoplasms 01/2022
1	COVID-19 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Alopecia (Baldness) 12/2020
1	Lymphedema (Milroy Disease) 01/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2019
1	Cognitive Dysfunction 01/2019
1	Chronic Disease (Chronic Diseases) 01/2018
1	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2016
1	Hyperplasia 02/2016
1	Hypertension (High Blood Pressure) 12/2014
1	Thrombosis (Thrombus) 01/2006

Drug/Important Bio-Agent (IBA)

7	Hormones (Hormone)IBA 11/2023 - 07/2016
5	Trastuzumab (Herceptin)FDA Link 07/2021 - 12/2014
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2015
3	palbociclibIBA 11/2023 - 01/2022
3	Fulvestrant (Faslodex)FDA Link 01/2023 - 04/2018
3	Aurora Kinase AIBA 01/2023 - 04/2018
3	ErbB Receptors (EGF Receptor)IBA 10/2022 - 12/2014
3	Estrogen ReceptorsIBA 01/2020 - 02/2016
3	human ERBB2 proteinIBA 09/2017 - 02/2016
2	Anastrozole (Arimidex)FDA LinkGeneric 05/2024 - 01/2021
2	Estrogens (Estrogen)FDA Link 05/2024 - 01/2021
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 08/2017
2	AnthracyclinesIBA 01/2023 - 01/2020
2	MLN 8237IBA 01/2023 - 04/2018
2	Cyclin-Dependent Kinase 4IBA 11/2022 - 01/2022
2	Lapatinib (GW572016)FDA Link 07/2021 - 07/2015
2	Docetaxel (Taxotere)FDA Link 01/2021 - 08/2017
1	Estrone FDA Link 05/2024
1	Estradiol (Delestrogen)FDA LinkGeneric 05/2024
1	RNA (Ribonucleic Acid)IBA 01/2024
1	ruxolitinibIBA 01/2024
1	berzosertibIBA 04/2022
1	Cisplatin (Platino)FDA LinkGeneric 04/2022
1	PlatinumIBA 04/2022
1	Phenobarbital (Luminal)FDA Link 01/2022
1	Capecitabine (Xeloda)FDA Link 07/2021
1	cixutumumabIBA 07/2021
1	sapanisertibIBA 01/2021
1	Everolimus FDA Link 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	exemestane (Aromasin)FDA Link 01/2021
1	enzalutamideIBA 01/2020
1	Androgen Receptors (Androgen Receptor)IBA 01/2020
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2017
1	neratinibIBA 07/2016
1	Carboplatin (JM8)FDA LinkGeneric 07/2016
1	veliparibIBA 07/2016
1	Drug CombinationsIBA 07/2015
1	Tyrosine Kinase InhibitorsIBA 07/2015

Therapy/Procedure

16	Therapeutics 01/2024 - 12/2014
11	Drug Therapy (Chemotherapy) 11/2023 - 01/2006
4	Neoadjuvant Therapy 01/2022 - 05/2015
3	Mastectomy (Mammectomy) 07/2023 - 01/2018
2	Segmental Mastectomy (Lumpectomy) 07/2023 - 03/2023
2	Aftercare (After-Treatment) 01/2020 - 01/2020
2	Adjuvant Chemotherapy 01/2018 - 08/2017
1	Immunotherapy 01/2024
1	Integrative Oncology 01/2023
1	Complementary Therapies (Alternative Medicine) 12/2020
1	Radiotherapy 03/2018